TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7952370

Group type: EXPERIMENTAL
Intervention: Home care services
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Independent weekly assessments
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Demographic and illness factors
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Psychological factors assessments
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Preference for inpatient care
Number of subjects: 415
Study: 3454893

Group type: EXPERIMENTAL
Intervention: Sending lists of infants due for immunisation to general practitioners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sending immunisation reminder cards to parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparable controls)
Number of subjects: 0
Study: 31715306

Group type: EXPERIMENTAL
Intervention: Follistatin (FS) and soluble endoglin (sEng) levels measured at day +28 post-HCT
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Pre-HCT measurements of FS and sEng
Number of subjects: 221
Study: 29802750

Group type: EXPERIMENTAL
Intervention: Pseudo-maximum likelihood estimation for site-occupancy models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maximum likelihood estimator of species-environment relationships
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations assessing modeling data sets
Number of subjects: 0
Study: 28699886

Group type: EXPERIMENTAL
Intervention: IL-1 trap rilonacept (160 mg/week) for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 39
Study: 25503808

Group type: EXPERIMENTAL
Intervention: Day 6 recombinant FSH priming
Number of subjects: 40

Group type: COMPARATOR
Intervention: No FSH priming
Number of subjects: 40
Study: 22941967

Group type: EXPERIMENTAL
Intervention: Encircling ipsilateral pulmonary veins isolation (EIPVsI) with the double-Lasso technique
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Non-isolation of the PV carina after EIPVsI
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pacing from the PV carina
Number of subjects: 81
Study: 21106014

Group type: EXPERIMENTAL
Intervention: Clopidogrel + PPI
Number of subjects: 49

Group type: COMPARATOR
Intervention: Clopidogrel only
Number of subjects: 49
Study: 18172922

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DUS)
Number of subjects: 88
Study: 16981859

Group type: EXPERIMENTAL
Intervention: Double-dose CEE/MPA (conjugated equine estrogens plus medroxyprogesterone acetate, 0.625 mg + 2.5 mg) daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Single-dose CEE/MPA (0.625 mg + 2.5 mg) daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CEE/MPA (both doses)
Number of subjects: 21
Study: 14614086

Group type: EXPERIMENTAL
Intervention: Right amygdala damage
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Left amygdala damage
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bilateral amygdala damage
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 61
Study: 11740262

Group type: EXPERIMENTAL
Intervention: G-CSF (2 microg/kg subcutaneously once a day for 5 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (sterilized saline)
Number of subjects: 25
Study: 9652562

Group type: EXPERIMENTAL
Intervention: Single-chamber atrial pacing
Number of subjects: 225
Study: 7659880

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3540764

Group type: EXPERIMENTAL
Intervention: Real Acupuncture
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo Acupuncture
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard Control
Number of subjects: 43

Group type: COMPARATOR
Intervention: Visitation Control
Number of subjects: 43
Study: 30942028

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (once a day, 5 treatments a week for 4 weeks) at points Baihui (BL 20), Fengchi (GB 20), Pishu (BL 20), Shenshu (BL 23), Sanyinjiao (SP 6), Taixi (KI 3)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group received oryzanol and vitamin B1 with rest and physical exercise
Number of subjects: 68
Study: 28426260

Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cessation of dapagliflozin
Number of subjects: 56
Study: 25731671

Group type: EXPERIMENTAL
Intervention: CABG (Isolated coronary artery bypass grafting)
Number of subjects: 2553
Study: 23527721

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 70
Study: 21672213

Group type: EXPERIMENTAL
Intervention: Immediate insertion of intrauterine contraception after second trimester abortion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed insertion of intrauterine contraception at 4 weeks post-abortion
Number of subjects: 0
Study: 19491213

Group type: EXPERIMENTAL
Intervention: Daily intake of a combination pill of 2.5 mg folic acid, 50 mg vitamin B6, and 1 mg vitamin B12
Number of subjects: 5242

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 5242
Study: 16967040

Group type: EXPERIMENTAL
Intervention: NNRTI (efavirenz)
Number of subjects: 291

Group type: COMPARATOR
Intervention: NRTI (stavudine)
Number of subjects: 291

Group type: COMPARATOR
Intervention: PI (ritonavir-boosted amprenavir)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 291
Study: 12739919

Group type: EXPERIMENTAL
Intervention: Nutrition counseling plus a nutritional supplement (Study) for 90 days
Number of subjects: 92

Group type: COMPARATOR
Intervention: Nutrition counseling alone (Control)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Nutrition counseling plus a nutritional supplement (Study)
Number of subjects: 92
Study: 10972607

Group type: EXPERIMENTAL
Intervention: sufentanil-midazolam (SM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: remifentanil-propofol (RP)
Number of subjects: 40
Study: 8832480

Group type: EXPERIMENTAL
Intervention: Flap debridement surgery + 100 mg/ml TTC solution and FFSS application
Number of subjects: 11

Group type: COMPARATOR
Intervention: Flap debridement surgery alone (control)
Number of subjects: 11
Study: 1418403

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3871235

Group type: EXPERIMENTAL
Intervention: Urea treatment during cardiopulmonary bypass
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (placebo) during cardiopulmonary bypass
Number of subjects: 48
Study: 30054088

Group type: EXPERIMENTAL
Intervention: 15.8 mm scleral lens (L1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 18 mm scleral lens (L2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both lenses (L1 and L2)
Number of subjects: 21
Study: 30053634

Group type: EXPERIMENTAL
Intervention: Brief combined parent‐based intervention (CBT‐based bibliotherapy plus doll)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 68
Study: 27367745

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% four times daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% four times daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 80
Study: 25156687

Group type: COMPARATOR
Intervention: No information about the effects of PCI on MI risk
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Specific statement that PCI does not reduce MI risk
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Explanation of why PCI does not reduce MI risk
Number of subjects: 1257
Study: 21901316

Group type: EXPERIMENTAL
Intervention: 1,017 μg salvinorin A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 μg salvinorin A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study: 20871954

Group type: EXPERIMENTAL
Intervention: Cervical headgear alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cervical headgear and lower utility arch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 17114190

Group type: EXPERIMENTAL
Intervention: MM-093 (21 mg weekly subcutaneous injections)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16623018

Group type: EXPERIMENTAL
Intervention: Diabetes drug counseling by pharmacist, diabetes booklet, and special medication containers
Number of subjects: 360

Group type: COMPARATOR
Intervention: Diabetes drug counseling by pharmacist
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All interventions (drug counseling, booklet, containers)
Number of subjects: 360
Study: 12131506

Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate + 70% isopropyl alcohol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70% isopropyl alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% aqueous chlorhexidine
Number of subjects: 0
Study: 10440120

Group type: EXPERIMENTAL
Intervention: Intensive diet-exercise programme
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group (general information about lifestyle changes)
Number of subjects: 523
Study: 9164416

Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (400 mg every 8 hours for 30 days) + Rifampin (600 mg once-daily on days 16-30)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Delavirdine mesylate (400 mg every 8 hours for 30 days)
Number of subjects: 12
Study: 1774018

Group type: EXPERIMENTAL
Intervention: Constant rate iv infusion of insulin (0.034 U/kg/h) during 150 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Identical infusion of insulin with variable iv infusion of glucose to maintain euglycemia
Number of subjects: 8
Study: 7075642

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg
Number of subjects: 10
Study: 31399128

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 28412602

Group type: EXPERIMENTAL
Intervention: Medication management plus full CBT
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Medication management plus instructions in CBT
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication management
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Child‐rated depression
Number of subjects: 124
Study: 26781346

Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim 100 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim 6 mg fixed dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily rhG-CSF
Number of subjects: 0
Study: 24963611

Group type: EXPERIMENTAL
Intervention: Usual care plus 6 months of telephone coaching
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 94
Study: 22543063

Group type: EXPERIMENTAL
Intervention: PER3(5/5) genotype
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: PER3(4/4) genotype
Number of subjects: 279

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 279
Study: 20139790

Group type: EXPERIMENTAL
Intervention: Active-commute (walking) group
Number of subjects: 40
Study: 18589022

Group type: EXPERIMENTAL
Intervention: Parental feeding practices (encouraging, modeling, restriction, pressure to eat, responsibility, monitoring)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Parental feeding practices (restriction, pressure to eat, monitoring)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Parental feeding practices (responsibility, restriction, monitoring, modeling)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Parental feeding practices (modeling, restriction)
Number of subjects: 239
Study: 16171591

Group type: EXPERIMENTAL
Intervention: RCAVF
Number of subjects: 383

Group type: COMPARATOR
Intervention: Prosthetic AVF
Number of subjects: 383

Group type: COMPARATOR
Intervention: Prosthetic graft
Number of subjects: 383
Study: 12047460

Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 1000-2000 mg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 10080417

Group type: EXPERIMENTAL
Intervention: Slow oscillating inflation
Number of subjects: 622

Group type: COMPARATOR
Intervention: Fast inflation
Number of subjects: 622
Study: 7745334

Group type: EXPERIMENTAL
Intervention: Bismuth subgallate as a haemostatic agent
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no haemostatic substance)
Number of subjects: 100
Study: 2039103

Group type: EXPERIMENTAL
Intervention: Rectal thiopental 25 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Drug combination (meperidine 2 mg/kg, promethazine 1 mg/kg, chlorpromazine 1 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Drug combination
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 6988030

Group type: EXPERIMENTAL
Intervention: Foam elastomer dressing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional gauze packing
Number of subjects: 50
Study: 29698971

Group type: EXPERIMENTAL
Intervention: Wound-edge protector (WEP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No wound-edge protector (WEP (-))
Number of subjects: 102
Study: 28658177

Group type: EXPERIMENTAL
Intervention: Real MENS
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham MENS
Number of subjects: 38
Study: 25824248

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation with the Symplicity Flex Catheter (Medtronic)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 71
Study: 23302898

Group type: EXPERIMENTAL
Intervention: Preemptive pain medication and intraoperative periarticular injections (Group I)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Not receiving preemptive medication and injections (Group II)
Number of subjects: 82
Study: 22766210

Group type: COMPARATOR
Intervention: Group I: Fentanyl 2 mg/kg + Pentothal 5 mg/kg + Vecuronium 0.1 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group II: Lidocaine 1.5 mg/kg + Fentanyl 2 mg/kg + Pentothal 5 mg/kg + Vecuronium 0.1 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group III: Lidocaine 1.5 mg/kg + Pentothal 5 mg/kg + Vecuronium 0.1 mg/kg
Number of subjects: 3
Study: 19408291

Group type: EXPERIMENTAL
Intervention: Elective selective I, II, III neck dissection (END)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 71
Study: 17264340

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy
Number of subjects: 415

Group type: COMPARATOR
Intervention: Intravenous (IV) chemotherapy
Number of subjects: 415
Study: 15333479

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin E per day for 3 months, increased to 1,200 IU per day for a further 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 80
Study: 11465092

Group type: EXPERIMENTAL
Intervention: Intermittent IL-2 therapy
Number of subjects: 11
Study: 9486289

Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8033433

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human albumin 5% (placebo)
Number of subjects: 0
Study: 2347035

Group type: EXPERIMENTAL
Intervention: Group A (two intradermal injections on days 0, 3, and 7)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Group B (one intradermal and one subcutaneous injection on days 0, 3, and 7)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Group C (two subcutaneous injections on days 0, 3, and 7)
Number of subjects: 44
Study: 465440

Group type: EXPERIMENTAL
Intervention: 5 g guar gum in bread
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5 g guar gum in soup
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 10 g guar gum (5 g in bread and 5 g in soup)
Number of subjects: 5
Study: 31901395

Group type: EXPERIMENTAL
Intervention: Bair Hugger (BH)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Inditherm (IT)
Number of subjects: 90
Study: 30632290

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg subcutaneous daily for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28950268

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet
Number of subjects: 1826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1826
Study: 25451179

Group type: EXPERIMENTAL
Intervention: QUEST A (latissimus dorsi breast reconstruction with postmastectomy radiotherapy unlikely)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: QUEST B (latissimus dorsi breast reconstruction with postmastectomy radiotherapy highly probable)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: QUEST Perspectives Study (QPS)
Number of subjects: 124
Study: 23876359

Group type: EXPERIMENTAL
Intervention: Experimental external nasal dilator strips (ENDS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo external nasal dilator strips
Number of subjects: 48
Study: 21880029

Group type: EXPERIMENTAL
Intervention: 20mg rociverine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 111
Study: 19588122

Group type: EXPERIMENTAL
Intervention: High or very low tryptophan/LNAA ratios
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Tyrosine/LNAA ratios
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Phenylalanine levels
Number of subjects: 97
Study: 17874921

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy with high treatment fidelity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multisystemic therapy with low treatment fidelity
Number of subjects: 40
Study: 15337691

Group type: EXPERIMENTAL
Intervention: Invasive strategy (n=153)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Optimized medical strategy (n=148)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Both invasive and medical strategies
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 276

Group type: COMPARATOR
Intervention: Optimized medical strategy
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Revascularization within the first year
Number of subjects: 276
Study: 11535214

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 79
Study: 9758290

Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin once daily
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 100 mg trovafloxacin once daily
Number of subjects: 412

Group type: COMPARATOR
Intervention: 500 mg amoxicillin three times daily
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 100 mg trovafloxacin
Number of subjects: 412

Group type: COMPARATOR
Intervention: 500 mg amoxicillin
Number of subjects: 412
Study: 8152575

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg/day (IV before chemotherapy and orally for 4 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ondansetron 8 mg x 3/day (first dose IV before chemotherapy and subsequent doses orally until the end of the fourth day after chemotherapy)
Number of subjects: 40
Study: 3072830

Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine (S-CMC) syrup
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 31526225

Group type: EXPERIMENTAL
Intervention: IIV4
Number of subjects: 346

Group type: COMPARATOR
Intervention: IIV3
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Both IIV4 and IIV3
Number of subjects: 346
Study: 31209699

Group type: EXPERIMENTAL
Intervention: Vaginal Dilators (VD) used for 3 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard guidance from the health team (Control Group)
Number of subjects: 88
Study: 28801400

Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Riluzole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26059253

Group type: EXPERIMENTAL
Intervention: Multidimensional intervention including engineering, organizational, and behavioral elements
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Number of subjects: 282
Study: 23181712

Group type: EXPERIMENTAL
Intervention: Ingesting all medications upon awakening
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Ingesting ≥1 medications at bedtime
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Ingesting all medications at bedtime
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Bedtime treatment with ARBs
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Bedtime treatment with calcium channel blockers
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Ingesting ≥1 medications at bedtime (specifically ARBs)
Number of subjects: 2156
Study: 21698340

Group type: EXPERIMENTAL
Intervention: Speed-dependent treadmill training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Steady speed treadmill training (Control)
Number of subjects: 26
Study: 19932838

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg/kg (group D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg and midazolam 0.075 mg/kg (group DM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 120
Study: 16687084

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 15110930

Group type: EXPERIMENTAL
Intervention: Congenital adrenal hyperplasia (CAH)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Unaffected relatives
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Prenatal androgens
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Handedness
Number of subjects: 128
Study: 11142926

Group type: EXPERIMENTAL
Intervention: Willow bark extract (240 mg salicin/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Willow bark extract
Number of subjects: 78
Study: 9350955

Group type: EXPERIMENTAL
Intervention: Quetiapine (407 mg mean daily dose)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Chlorpromazine (384 mg mean daily dose)
Number of subjects: 201